Arcturus Therapeutics, Inc.
Quick facts
Phase 3 pipeline
- ARCT-2303 · Oncology
ARCT-2303 is a self-amplifying RNA (saRNA) vaccine that encodes tumor-associated antigens to stimulate CD8+ T-cell immune responses against cancer cells. - Influenza vaccine, adjuvanted · Immunology
An adjuvanted influenza vaccine that enhances immune response through the addition of an adjuvant to improve antibody production and cellular immunity against influenza virus strains. - Placebo booster
A placebo booster is a formulation designed to enhance the placebo effect through optimized delivery or presentation characteristics.
Phase 2 pipeline
- ARCT-021 Dose 1 · Infectious Diseases
ARCT-021 is a mRNA-based vaccine. - ARCT-032
- ARCT-810 · Oncology
ARCT-810 is a self-amplifying RNA (saRNA) therapeutic that encodes a secreted form of arginase-1 to modulate immune responses in cancer.
Phase 1 pipeline
- ARCT-021 Dose Regimen 1
- ARCT-021 Dose Regimen 2
- ARCT-154
- ARCT-165
- ARCT-2138
- ARCT-2304
- Control vaccine older adults
- Control vaccine younger adults
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: